198
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Single-dose pharmacokinetics and dose proportionality of intravenous pazufloxacin mesilate in healthy Korean volunteers

, , , , , , & (Clinical Professor) (Associate Professor) (Clinical Professor) (Associate Professor) show all
Pages 921-928 | Published online: 18 Jul 2012

Bibliography

  • Johnson AP. Pazufloxacin Toyama Chemical Co. Curr Opin Investig Drugs 2000;1:52-7
  • Fukuoka Y, Ikeda Y, Yamashiro Y, In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother 1993;37:384-92
  • Niki Y, Watanabe S, Yoshida K, Effect of pazufloxacin mesilate on the serum concentration of theophylline. J Infect Chemother 2002;8:33-6
  • Mikamo H, Sato Y, Hayasaki Y, In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients. Chemotherapy 1999;45:154-7
  • Liu Y-F, Huang K-L, Peng D-M, Preparation and characterization of glutaraldehyde cross-linked O-carboxymethylchitosan microspheres for controlled delivery of pazufloxacin mesilate. Int J Biol Macromol 2007;41:87-93
  • Minami S, Hattori R, Matsuda A. Pharmacological properties and expected clinical role of an injectable new quinolone antibiotic, pazufloxacin mesilate. Nippon Yakurigaku Zasshi 2003;122:161-78
  • Phapale PB, Lee HW, Kim SD, Analysis of pazufloxacin mesilate in human plasma and urine by LC with fluorescence and UV detection, and its application to pharmacokinetic study. Chromatographia 2010;71:101-6
  • Boom S, Talluri K, Janssens L, Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009;49:1318-30
  • Smith BP, Vandenhende FR, DeSante KA, Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-83
  • Karhu D, Groenewoud G, Potgieter MA, Mould DR. Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions. J Clin Pharmacol 2010;50:1438-49
  • Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med 2008;38:32-46
  • Yamaki K-I, Hasegawa T, Matsuda I, Pharmacokinetic characteristics of a new fluoroquinolone, pazufloxacin, in elderly patients. J Infect Chemother 1997;3:97-102
  • Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: concepts and applications. 2011; 4th edition. Lippincott Williams & Wilkins; Philadelphia
  • Alvarez AI, Pérez M, Prieto JG, Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 2008;97:3483-93
  • Shimizu A, Miyoshi M, Sugie M, Possible involvement of P-glycoprotein in renal excretion of pazufloxacin in rats. Eur J Pharmacol 2004;501:151-9
  • Hagenbuch B. Drug uptake systems in liver and kidney: a historic perspective. Clin Pharmacol Ther 2010;87:39-47

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.